DI-017



#### SAFETY OF NAB-PACLITAXEL PLUS GEMCITABINE IN PATIENTS WITH METASTATIC PANCREATIC CANCER

MD Cantudo Cuenca<sup>1</sup>, MR Cantudo Cuenca<sup>2</sup>, A Acuña Vega<sup>1</sup>, T Diaz Redondo<sup>3</sup>, D Blanquez Martinez<sup>4</sup>, JF Marín Pozo<sup>1</sup>, F Horno Ureña<sup>1</sup>.

1Complejo Hospitalario Jaén, Pharmacy Service, Jaén, Spain. 2Area Hospitalaria Valme, Pharmacy Service, Sevilla, Spain. 3Complejo Hospitalario Jaén, Oncology Service, Jaén, Spain. 4San Cecilio University Hospital, Pharmcy Service, Granada, Spain.

## **BACKGROUND**

PANCREATIC CANCER REMAINS A HIGHLY FATAL AND DIFFICULT TO-TREAT DISEASE.

NAB-PACLITAXEL (NAB-P), AN ALBUMIN-BOUND FORMULATION OF PACLITAXEL, APPEARS TO DECREASE LEVELS OF CYTIDINE DEAMINASE, WHICH IS THE PRIMARY GEMCITABINE CATABOLIC ENZYME, THIS LIKELY INCREASES SENSITIVITY TO GEMCITABINE (GEM) WHEN THESE AGENTS ARE COMBINED.

# PURPOSE

✓ TO EVALUATE THE SAFETY OF GEM PLUS NAB-P USED OFF LABEL IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (PDA).

✓ TO COMPARE THE INCIDENCE OF ADVERSE EVENTS (AES) WITH CLINICAL TRIAL RESULTS.

## **MATERIALS AND METHODS**

✓ RETROSPECTIVE OBSERVATIONAL STUDY (JANUARY 2011-OCTOBER 2012)

#### **INCLUSION CRITERIA**

ALL PATIENTS WITH PDA WHO RECEIVED GEM 1000 MG/M2 FOLLOWED BY NAB-P AT 100 MG/M2 WEEKLY FOR 3 WEEKS ON AN EVERY-4-WEEK CYCLE.

✓THE INFORMATION WAS EXTRACTED FROM PATIENTS MEDICAL RECORDS AND FROM PHARMACY SERVICE RECORDS.


#### VARIABLES

✓ DEMOGRAPHICS (sex-age)

✓ PREVIOUS TREATMENT

✓ DOSAGE REDUCTION AND TOXICITY

✓ AES WERE GRADED ACCORDING TO NCI-CTCAEV4.



## **CONCLUSIONS**

ALL ADVERSE EVENTS OBSERVED WERE REPORTED IN CLINICAL TRIAL. THESE PATIENTS REQUIRE CLOSE MONITORING DURING TREATMENT.



JUNTA DE ANDALUCI

Servicio Andaluz de Salud CONSEJERÍA DE IGUALDAD.

SALUD Y POLÍTICAS SOCIALES